NeuroPace RNS System
NeuroPace, Inc. · Decision date May 28, 2026
What did the FDA approve?
FDA records P100026/S101 as a supplement to PMA P100026, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated May 28, 2026.
FDA approval order statement
approval for an optional Electrocorticogram (ECoG) Assistant function, which is a clinician tool that highlights ECoG recordings of interest, for the Patient Data Management System.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Neurology
- Decision date
- May 28, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P100026/S101
- Regulatory pathway
- PMA supplement
- Applicant
- NeuroPace, Inc.
- Product code
- PFN
- Decision code
- APPR
- Decision date
- May 28, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implanted brain stimulator for epilepsy.
- Applicant
- NeuroPace, Inc.
- Product code
- PFN
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P100026/S101 received
Application receipt date recorded by FDA.
P100026/S099 · Related supplement
NeuroPace RNS System
P100026/S103 · Related supplement
NeuroPace RNS System
P100026/S101 · FDA decision
Normal 180 Day Track
P100026/S100 · Related supplement
NeuroPace RNS System
P100026/S104 · Related supplement
NeuroPace RNS System
Timeline entries are records held by MedtechLedger for P100026. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P100026
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
NeuroPace RNS SystemP100026/S099 | NeuroPace, Inc. | PMA supplement | Aug 18, 2025 | FDA |
NeuroPace RNS SystemP100026/S103 | NeuroPace, Inc. | PMA supplement | Feb 20, 2026 | FDA |
NeuroPace RNS SystemP100026/S100 | NeuroPace, Inc. | PMA supplement | Jun 17, 2026 | FDA |
NeuroPace RNS SystemP100026/S104 | NeuroPace, Inc. | PMA supplement | Aug 19, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
NeuroPace, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 455 N Bernardo Ave., Mountain View, CA, 94043
Sources and methodology
- Original FDA record: P100026/S101
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records